Globus Medical (GMED) Q2 2026: EBITDA Margin Jumps 740bps as Spine and Trauma Outpace Market
Globus Medical’s Q2 2026 delivered a decisive margin inflection, with EBITDA margin up 740 basis points, as core U.S. and international spine and trauma segments extended share gains even as enabling tech and Nevro integration tempered headline growth. Strategic execution on cost, product launches, and commercial expansion signal a business shifting from integration mode to scalable, above-market growth, with capital allocation and innovation setting the stage for further operating leverage into 2027.
Summary
- Margin Expansion Accelerates: Operating leverage from supply chain and integration drove a step-change in profitability.
- Spine and Trauma Outperform: Core musculoskeletal segments gained share, offsetting enabling tech and Nevro drag.
- Strategic Capital Deployment: Share repurchases and R&D investments reinforce a transition to sustainable, innovation-led growth.
Business Overview
Globus Medical is a global musculoskeletal technology company focused on developing, manufacturing, and commercializing medical devices and technologies for spine, trauma, enabling technologies, and neuromodulation. The company generates revenue through implantable devices, capital equipment, disposables, and related services. Its major segments include U.S. and international spine, trauma, enabling technologies (robotics and navigation), and the recently acquired Nevro, neuromodulation for pain management.
Performance Analysis
Globus Medical’s Q2 2026 marked a clear pivot toward higher profitability, with adjusted EBITDA margin reaching 35.4%, up 740 basis points year-over-year, and non-GAAP EPS up 56% over the prior year quarter. Revenue grew 6% as reported, but core growth excluding Nevro was 9%, led by U.S. spine (7% growth) and international spine (14% growth), both outpacing global peers and confirming sustained share gains. Trauma revenue surged 31%, driven by product launches and supply normalization, while enabling technologies (robotics and navigation) declined 26% as the capital acquisition model shifted toward leasing and rentals.
Musculoskeletal revenue (spine and trauma) accounted for the lion’s share of results, with broad-based strength across geographies and product lines. International expansion (18% YoY growth) was driven by set deliveries and inventory availability, especially in EMEA, APAC, and LATAM. The Nevro business, while flat sequentially, showed early signs of operational stabilization, with Salesforce expansion and margin improvement (EBITDA margin from negative 1.4% to 22.4% YoY) after integration actions. Gross margin improved to 69.4%, with management reiterating a path back to mid-70s as manufacturing and supply chain synergies compound.
- Spine Share Gains Endure: U.S. and international spine outgrew the market, driven by new products and competitive recruiting.
- Trauma Growth Accelerates: 31% YoY growth as supply chain constraints eased and portfolio differentiation attracted new customers.
- Enabling Tech Model Shifts: Revenue declined as more units were leased or rented, but placements rose, supporting future implant pull-through.
Cost discipline and capital allocation were evident, with SG&A and R&D leverage, and $136 million in share repurchases (40% of YTD free cash flow) supporting both near-term EPS and long-term innovation capacity.
Executive Commentary
"We've successfully demonstrated our ability to bring together the two best in class buying portfolios while expanding our commercial distribution and operating with a sense of urgency in a manner that exhibits financial discipline through earnings accretion and increasing returns on capital."
Keith Pfeil, President and Chief Executive Officer
"Our second quarter results delivered above-market top-line growth, including share-taking domestic and international spine sales growth, our seventh consecutive quarter of adjusted gross profit margin expansion, and a quarterly record for fully diluted non-GAAP earnings per share."
Kyle Klin, Chief Financial Officer
Strategic Positioning
1. Core Musculoskeletal Platform Expansion
Globus Medical’s organic product development engine remains a competitive differentiator, with over 25 launches in 36 months and 60+ projects in the pipeline. Spine and trauma portfolios are expanding both breadth and depth, enabling the company to serve more procedure types and clinical needs, while the exclusive direct salesforce model accelerates commercial execution and market share capture.
2. Enabling Technologies Model Transformation
The shift to flexible capital acquisition (leasing, rentals) in enabling technologies is intentionally lowering reported revenue but raising unit placements (up 25% YoY). This strategy is designed to drive “pull-through” of higher-margin implant, disposable, and service revenue, supporting durable growth in the core musculoskeletal business and aligning with customer capital budgeting realities.
3. Nevro Integration and Margin Recapture
Structural changes in Nevro’s product development, sales, and G&A functions have rapidly improved profitability, with EBITDA margin now above 20%. Salesforce expansion and training are restoring field capacity, with trial volumes expected to recover to historical levels by Q4, setting the stage for a return to growth in 2027.
4. Manufacturing and Supply Chain Synergy Execution
Cost initiatives in manufacturing and supply chain have driven consistent gross margin expansion, with management targeting a return to mid-70s adjusted gross margin. Fixed cost leverage, synergy capture, and improved set deliveries are supporting both U.S. and international expansion while freeing up resources for R&D investment.
5. Data, Analytics, and Surgical Intelligence Ecosystem
Globus is investing in a surgical intelligence ecosystem integrating implants, enabling tech, procedural solutions, and AI-driven analytics, aiming to improve patient selection, surgical execution, and outcomes. This digital strategy is intended to create a differentiated, scalable platform that compounds clinical and commercial advantage over time.
Key Considerations
This quarter’s results reflect a business transitioning from integration and cost capture to scalable, innovation-driven growth, with margin expansion and capital deployment reinforcing a multi-year competitive position.
Key Considerations:
- Margin Inflection Validates Integration: 740bps EBITDA margin expansion signals successful synergy capture and operational discipline.
- Product Launch Cadence Remains High: Over 60 projects in development, with patient-specific implants and digital solutions set to launch in H2.
- International Execution Gains Traction: Set deliveries and inventory availability underpin sustained double-digit growth targets outside the U.S.
- Enabling Tech Model Dilutes Near-Term Revenue: Leasing/rental strategy depresses reported sales but increases placements for future pull-through.
- Capital Allocation Balances Buybacks and R&D: Share repurchases reduce dilution, while ramped R&D spend in H2 supports long-term innovation.
Risks
Key risks include execution on Nevro’s return to growth, the pace of enabling tech pull-through to implants, and potential macro or regulatory disruptions in international markets. Margin expansion is partially reliant on continued supply chain and manufacturing initiatives, and any delays or inflationary pressures could moderate progress. Competitive intensity in spine and trauma remains high, with market share gains requiring sustained commercial investment.
Forward Outlook
For Q3 2026, Globus Medical guided to:
- Continued double-digit international spine growth
- Sequential gross margin improvement, targeting 69–70% for full year
For full-year 2026, management raised non-GAAP EPS guidance to $4.95–$5.05 (from $4.70–$4.80) and reaffirmed revenue guidance of $3.18–$3.22 billion.
Management highlighted:
- Margin expansion and operating leverage as key drivers of upgraded EPS outlook
- Ongoing R&D ramp and product launches to support H2 growth
Takeaways
Globus Medical’s Q2 results signal a business that has absorbed recent integrations and is now leveraging scale, cost discipline, and innovation to drive both top-line and bottom-line outperformance.
- Margin Expansion Is Durable: 740bps EBITDA improvement reflects lasting operational changes, not one-off gains.
- Core Growth Engines Are Intact: U.S. and international spine, plus trauma, are offsetting Nevro and enabling tech drag, with share gains evident.
- H2 Will Test Pull-Through and Innovation: Watch for implant growth from enabling tech placements and the impact of new product launches on revenue and margin.
Conclusion
Globus Medical exits Q2 2026 with clear momentum in margin, product innovation, and commercial execution, positioning the company to deliver on its guidance and compound operating leverage into 2027. Sustained investment in R&D and digital ecosystem build-out, alongside disciplined capital allocation, support a thesis of durable, above-market growth and expanding returns on capital.
Industry Read-Through
Globus Medical’s margin and international expansion validate the scalability of integrated musculoskeletal platforms, with supply chain discipline and product innovation as key differentiators. The shift to flexible capital models in robotics and navigation is likely to become industry standard, favoring companies with strong implant pull-through and service capabilities. Market share gains in spine and trauma indicate that commercial execution and product breadth remain critical in a fragmented, competitive landscape, while digital and AI-driven surgical intelligence investments signal the next frontier for differentiation across orthopedics and medtech.